Primary record
5-Heptenoic acid, 7-(6-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1-alpha,4-alpha,5-beta(Z),6-alpha(1E,3S*)))-
- 库存
- 6,015 克
- 纯度
- 98.3 %
- CAS
- 56985-40-1
化合物标识与属性
- CAS
- 56985-40-1
- PubChem CID
- 5311493
- SMILES
- CCCCC[C@@H](/C=C/[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)CO2)O
- Canonical SMILES
- CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@H]2CO[C@@H]1C2
名称与同义词
- 9,11-Methanoepoxy PGH2
- 9alpha-PGM
- U-46619
- 56985-40-1
- Thromboxane A2 agonist
- U46619
- Opera_ID_380
- 9,11-Epoxymethano-pgh2
- 9,11-Methanoxy-PGH2
- RefChem:1100620
- U 46619
- D03PLH
- D0Y6OL
- 9,11 epoxymethano PGH2
- MLS000028857
- CHEMBL521784
- 11alpha,9alpha-epoxymethano-PGH2
- BSPBio_001534
- BML1-G04
- DTXSID601028475
- GTPL1888
- GTPL1974
- orb1706500
- C21H34O4
- SCHEMBL12272421
- LQANGKSBLPMBTJ-BRSNVKEHSA-N
- LQANGKSBLPMBTJ-RTYMFESYNA-N
- DTXCID301514047
- DTXSID401364847
- GLXC-15507
- HMS1361M16
- HMS1791M16
- HMS1989M16
- HMS2234N20
- HMS3402M16
- 9alpha,11alpha-Methanoepoxy-PGF2alpha
- GCA98540
- ZINC8716754
- BDBM50292409
- MFCD00135238
- 11 alpha,9 alpha Epoxymethano PGH2
- 11 alpha,9 alpha-Epoxymethano PGH2
- SMR000058897
- AKOS024456866
- 11-9 EM
- AT25012
- C21-H34-O4
- CID5311493
- 9salpha,11alpha-Methanoepoxy-PGF2alpha
- CID:5311493
- IDI1_034004
- [3H]U46619
- NCGC00161291-01
- NCGC00161291-02
- NCGC00161291-03
- [3H]U 46619
- DA-78735
- J23.637C
- MS-32668
- SID:53790278
- 11alpha,9alpha-Epoxymethanoprostaglandin H2
- HY-108566
- CS-0029178
- U44619
- U46619 (10 MG/ML IN METHYL ACETATE)
- 9a,11a-Methanoepoxy-15-hydroxyprosta-5,13-dienoic acid
- D019796
- U 44619
- U-44619
- U46,619
- Q4864593
- U 46,619
- 9,11-Dideoxy-9a,11a-methanoepoxy prostaglandin F2a
- 9,11-Dideoxy-9alpha,11alpha-methanoepoxy PGF2alpha
- BRD-K18757346-001-02-9
- 9,11-Dideoxy-11 alpha,9-alpha-epoxymethano-PGF2 alpha
- 9,11-Dideoxy-11|A,9|A-epoxymethanoprostaglandin F2|A
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
- 9,11-dideoxy-9.alpha.,11.alpha.-methanoepoxyprostaglandin F2alpha
- (Z)-7-[(1R,4S,5S,6R)-6-[(E,3S)-3-hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
- (Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid
- 9,11-Dideoxy-11alpha,9alpha-epoxymethanoprostaglandin F2alpha
- 9,11-dideoxy-9alpha,11alpha-methanoepoxy prostaglandin F2alpha
- U46619, U-46619, U 46619
- (15S)Hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid
- 9,11-Dideoxy-11 alpha,9 alpha-epoxymethanoprostaglandin F2 alpha
- (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid
- (5z)-7-{(1r,4s,5s,6r)-6-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-2-Oxabicyclo[2.2.1]hept-5-Yl}hept-5-Enoic Acid
- (Z)-7-((1R,4S,5S,6R)-6-((S,E)-3-Hydroxyoct-1-en-1-yl)-2-oxabicyclo[2.2.1]heptan-5-yl)hept-5-enoic acid
- (15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid
- (5Z,13E,15S)-15-Hydroxy-11alpha,9alpha-(epoxymethano)prosta-5,13-diene-1-oic acid
- (5Z)-7-[(1R,4S)-6beta-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]heptan-5alpha-yl]-5-heptenoic acid
- (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
- (Z)-7-((1R,4S,5S,6R)-6-((S,E)-3-hydroxyoct-1-enyl)-2-oxabicyclo[2.2.1]heptan-5-yl)hept-5-enoic acid
- (Z)-7-((1S,4R,5R,6S)-5-((E,3S)-3-hydroxyoct-1-enyl)-3-oxabicyclo(2.2.1)heptan-6-yl)hept-5-enoic acid
- (Z)-7-[(1R,4S)-6beta-[(E,S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5alpha-yl]-5-heptenoic acid
- 5-Heptenoic Acid, 7-(6-(3-Hydroxy-1-Ocentyl)-2-Oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1alpha,4alpha,5 beta(Z),6alpha(1E,3S*)))-
- 5-Heptenoic acid, 7-(6-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1-alpha,4-alpha,5-beta(Z),6-alpha(1E,3S*)))-
- 76898-47-0
- PUC
- U 46619,(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoicacid